|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 4. Xenopus Galntl-1 loss-of-function phenotype. (A)
Stage 40 uninjected control embryo and embryo injected radially with the
xGalntl-1-specific morpholinos at the 2- to 4-cell stage. Numbered lines
indicate the positions of the paraffin sections shown on the right that reveal
a reduction of neural tissue in the morpholino-injected embryos. (B)
Uninjected control embryo and embryos microinjected with xGalntl-1 morpholinos
stained with the notochord-specific antibody MZ15 at stage 40 (left) and
analysed by in situ hybridisation for slug expression at stage 30.
The morpholino-injected embryos display defects in the anterior notochord and
reduced anterior expression of slug. (C) Whole-mount in situ
hybridisation for slug of stage 15 embryos after radial
microinjection of the xGalntl-1 morpholinos at the 2- to 4-cell stage, and
stage 13 embryo stained for msx1 after single injections of the
xGalntl-1 morpholinos into a dorsal-animal blastomere at the 8-cell stage
together with lacZ mRNA. (D) RT-PCR analysis of stage 20
dorsal marginal zone explants from uninjected embryos or embryos microinjected
with xGalntl-1 morpholinos alone or together with xGalntl-1 mRNA (20
pg). The expression of otx2 and six3 (forebrain) as well as
of snail (neural crest) was inhibited by the xGalntl-1 morpholinos,
whereas the expression of dlx5 (epidermis), xvent2 (ventral
mesoderm) and xbra (mesoderm) was unaffected.
|
